However, satisfactory 24-h profile could be


However, satisfactory 24-h profile could be

accomplished by both PVP K30 and PVP K90-containing membrane at the range and membrane thickness tested. Preparation and testing of the optimized formulation showed a good correlation between predicted and observed values.”
“Blends based on LDPE and chitin or chitosan were prepared under high-temperature shear deformations in a rotor disperser at different initial ratios of the components. Although one of the components is an infusible polymer (polysaccharide), Rapamycin the powder blends were obtained. The composition of the powder fractions was shown to be identical to the original blend composition. It was found that the addition of poly(ethylene oxide) to the mentioned blends improves the biodegradability of the polymer materials and extends their application areas. Using various physicochemical methods, the structural and morphological changes in the polymer compositions under the action of shear deformations were examined, Copanlisib the mechanical characteristics of prepared films were determined, and also the features of their bio-, thermo-, and photo-oxidative degradation were studied. (c) 2011 Wiley Periodicals, Inc. J Appl Polym Sci 121: 1850-1859, 2011″

assess the long-term efficacy and safety of saxagliptin in patients with type 2 diabetes mellitus inadequately controlled with thiazolidinedione monotherapy, 565 patients were randomised to saxagliptin (2.5 mg or 5 mg) or placebo added to thiazolidinedione over 76 weeks (24-week short-term + 52-week long-term extension period) in this phase 3, double-blind, placebo-controlled trial; 360 patients completed the study. At 76 weeks,

adjusted mean changes from baseline HbA(1C) (repeated measures model; 95% CI) for saxagliptin 2.5 mg, 5 mg, and placebo were -0.59% (-0.75, -0.43), -1.09% (-1.26, -0.93), and -0.20% (-0.39, -0.01), respectively (post hoc and nominal p=0.0019 and p<0.000 I for saxagliptin 2.5 mg and 5 mg vs. placebo, respectively). Adverse event frequency was similar between groups. Confirmed hypoglycaemic events were 1.0% and 0% vs. 0.5% for saxagliptin 2.5 mg and 5 mg vs. placebo, respectively. Results should be interpreted with caution given the proportion MX69 of patients who discontinued or required glycaemic rescue therapy during the 76-week course of study. Saxagliptin added to thiazolidinedione provided sustained incremental efficacy vs. placebo with little hypoglycaemia for up to 76 weeks and was generally well tolerated.”
“The present paper was focused on exploiting Plackett-Burman design to screen the effect of nine factors-poly (ethylene oxide) molecular weight (X (1)), poly (ethylene oxide) amount (X (2)), ethylcellulose amount (X (4)), drug solubility (X (5)), drug amount (X (6)), sodium chloride amount (X (7)), citric acid amount (X (8)), polyethylene glycol amount (X (9)), and glycerin amount (X (11)) on the release of drugs from the extended release extrudates, i.e., release rate and release mechanism.

Comments are closed.